Transgene: Focus on 2013 with key milestones expected

CORPORATE, Fair Value EUR21 (+147%)

News published on March Friday 22, 2013
Share on

Transgene released its full year results with a EUR43.2m loss driven by R&D expenses (EUR48.7m) linked by TG4010 and JX594 clinical trials. The cash position is EUR92.9m at year end while Transgene expects cash consumption of EUR50m in 2013. 2013 will definitely be an important year for Transgene given the eagerly awaited clinical results of TG4010 and JX594.

Full report available to subscribers
Please contact  

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities